Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0344307 (analgesia)
 28,200 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The aim of the study was to investigate 1) whether laser treatment would enhance periodontal healing after debridement, 2) if laser treatment would facilitate instrumentation, and 3) if laser treatment would provide sufficient analgesia. The used apparatus produced radiation equivalent to a Nd:YAG-laser and was equipped with a water spray. 27 individuals with periodontitis took part in the study. Single-rooted teeth in one quadrant were assigned test teeth by lot with contralateral teeth serving as controls. Test areas were first laser irradiated to produce analgesia. The root surfaces were treated with the laser set at higher power and scaled with curettes followed by lasing again. Control areas were treated by scaling alone. Reduction of PPD and bleeding index after healing were similar in test and control areas. Laser treatment reduced the need of conventional anaesthetics, resulted in diminished bleeding and enhanced visual control at debridement. Thin calculus deposits were very easy to remove with hand instruments after lasing. The hemostatic effect of the laser may be an asset when performing periodontal scaling in individuals with a compromised coagulation mechanism.
 ...
PMID:Laser treatment as an adjunct to debridement of periodontal pockets. 1246 72

Dapoxetine [LY 210448], a selective serotonin reuptake inhibitor (SSRI), is structurally related to fluoxetine with antidepressant activity. Dapoxetine is the D-enantiomer of LY 243917 and is 3.5 times more potent as a serotonin reuptake inhibitor than the L-enantiomer. Dapoxetine was in phase I clinical trials in the US with Eli Lilly as an antidepressant, but no recent development has been reported for this indication. However, development is underway for the treatment of premature ejaculation, with phase III trials for this indication being completed in the US. The phase II trial for the treatment of premature ejaculation was conducted by PPD GenuPro, a subsidiary of PPD, which was established from a collaboration between Eli Lilly and PPD for the development of drugs to treat genitourinary disorders. Both Lilly and PPD had an option to re-license dapoxetine upon completion of phase II trials, but neither company exercised its option, and the rights remained with PPD GenuPro. In December 2003, PPD Inc. acquired from Eli Lilly and Co. the patents for dapoxetine for development in the field of genitourinary disorders. As part of the transaction, PPD and Lilly terminated their existing license agreement for dapoxetine. In December 2000, PPD GenuPro granted an exclusive, worldwide license for dapoxetine to ALZA Corporation, a wholly owned subsidiary of Johnson & Johnson. ALZA will be responsible for development, manufacturing and commercialisation of dapoxetine for urological indications, including premature ejaculation. It will make initial, milestone and royalty payments to PPD GenuPro, a portion of which will be paid to originator Eli Lilly. PPD Inc. received a milestone payment relating to the ongoing development of dapoxetine for premature ejaculation in July 2003. In December 2003, PPD and ALZA amended the dapoxetine license to allow PPD to receive a fixed-sum cash payment apon NDA approval. In return for this, ALZA will not have to make sales-based payments for a period of time following the approval of dapoxetine. If dapoxetine is approved by the US FDA for premature ejaculation, the drug will be marketed in the US by Ortho-McNeil Pharmaceutical, Inc. In December 2004, ALZA Corporation submitted a new drug application to the FDA for dapoxetine hydrochloride in the treatment of premature ejaculation. If approved by the FDA, dapoxetine hydrochloride will be marketed in the US by Ortho-McNeil Pharmaceutical, Inc. Johnson & Johnson plans to support the launch of dapoxetine for premature ejaculation with a 'responsible' direct-to-consumer advertising campaign. In May 2005, Johnson & Johnson presented data from two phase III trials involving dapoxetine for the treatment of premature ejaculation, during the 100th Annual Scientific Meeting of the American Urological Association (AUA-2005). Results on drug interactions and pharmacodynamics of dapoxetine were also presented during this meeting. Dapoxetine also appears to be a useful adjunct to morphine, lowering the threshold for analgesia, although the compound itself has negligible analgesic activity. In December 2003, PPD, Inc. acquired from Eli Lilly and Company the patents for dapoxetine for development in the field of genitourinary disorders. Under the terms of the agreement with Lilly, PPD will pay Lilly 65 million US dollars in cash. PPD will also pay Lilly a royalty on net sales of dapoxetine in excess of a certain threshold of annual net sales. As part of the transaction, PPD and Lilly terminated their existing license agreement for dapoxetine.
 ...
PMID:Dapoxetine: LY 210448. 1612 1